At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
Niraparibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety of Niraparib in Japanese Patients With Platinum-sensitive, Relapsed Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Achieved CR or PR in the Last Chemotherapy Containing Platinum-based Anticancer Agents
In Brief
A Phase 2 clinical trial evaluating Niraparib for Ovarian Cancer and 2 related conditions. Completed, enrolled 19 participants across 27 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of niraparib in Japanese participants with platinum-sensitive, relapsed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who achieved complete response (CR) or partial response (PR) in the last chemotherapy containing platinum-based anticancer agents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartDec 2018
Primary CompletionMar 2019
Study CompletionDec 2022
TodayJul 2026
First PostedNov 30, 2018
Enrollment StartDec 28, 2018
Primary CompletionMar 17, 2019
Study CompletionDec 28, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.6 years ago
Interventions
Niraparibdrug
Niraparib capsule